



CBD of Denver, Inc.

March 18, 2021

Marcel Gamma

President – CBD of Denver Inc.

CEO & Chairman – Swiss Industry Ventures AG





Project Vision


- ✦ Swiss Investment Company using the opportunities of the Swiss CBD Market
- ✦ Buying existing profitable but undervalued businesses at very attractive price
- ✦ Diverse team of experts and professionals from CBD Business, Finance, Operations and Sales
- ✦ Integration into existing and well established setup
- ✦ Development of customer base and sales extensively
- ✦ Exploring new markets - geographically and segment wise
- ✦ Developing the whole value chain for the CBD Business in Switzerland and Europe

“From Seed to Customer“



Competitive Advantage

- ✦ Unique advantage offered by the Swiss Market
- ✦ Legal to grow, produce and sell CBD products
- ✦ Only european country able to grow Cannabis up to 1% THC-Level
- ✦ In Switzerland you can legally buy and wash down CBD
- ✦ Excellent centralized setup to sell to European Market
- ✦ Swiss Quality Standard and Growing Cannabis Trend
- ✦ Cannabis Industry is still in its infancy stages in Switzerland and Europe
- ✦ Strong partnership with publicly traded US and Canadian companies





Achievements

- ✓ 5 Acquisitions done and successfully implemented
- ✓ Import Licence for Switzerland
- ✓ Expansion into European Market already done
- ✓ Exclusive partnerships with major players in Switzerland, Europe and Global
- ✓ Product Portfolio for Retail and Wholesale
- ✓ Over USD 16 million revenue achieved in 2020 with net profit of more than USD 700K
- ✓ Over USD 4.5 million revenue achieved for Jan/Feb 2021 even with COVID lockdown impact






Market Overview

In 2017, the **Swiss CBD Market** has generated a turnover of around CHF 60 million (\pm EUR 54 million). And according to CBD Intel, growth will continue, with forecasts indicating that the legal cannabis and CBD industry should reach a value of CHF 320 million (\pm € 288 million) by 2027.

According to the "European Cannabis Report", a market analysis by the British office of Prohibition Partners, a fully liberalized Swiss market would have a total potential of CHF 2.7 billion by 2028 - CHF 1.3 billion in the medical sector and CHF 1.4 billion in recreational use.


The chances for full liberalization are better than ever before. In June 2020, the Federal Council approved an amendment to the Narcotics Law, an imported further step on the way to full liberalization.



Source: CBD Intel

A close-up photograph of a cannabis flower bud. The bud is the central focus, showing a cluster of green, serrated bracts and numerous orange, hair-like trichomes. The surrounding leaves are green and serrated, but they are out of focus, creating a shallow depth of field. The lighting is soft and natural, highlighting the texture of the plant.

Growth Strategy




- ✦ **Merger & Acquisitions** will become a major focus in the Cannabis space in 2021/2022 for Swiss players
- ✦ **Critical mass will create market leaders** who will shape the industry. Leaders will stand out through **vertically integrated operation** with ability to **scale across the value chain**.
- ✦ **The Leading Players will become CBG (Consumer Branded Goods)** companies with diverse **portfolio of product brands across multiple consumer categories**.
- ✦ **Cannabis CBG companies will attract strategic alliances, investment and exit opportunities.**



Investment Opportunity

- ✦ Ability to buy CBD companies through its network at very attractive prices
- ✦ European Cannabis Industry is in its Infancy Stage
- ✦ Swiss Market 10-15 year behind US and CDN
- ✦ 5 Acquisitions already implemented and expanding into new business areas
- ✦ 2 additional projects in advanced planning stage
- ✦ The average multiple of 12.4 times enterprise value as per Haywood Capital Markets

REVENUES (MIO. CHF)
TOTAL 2020 USD 16.1 million





Swiss Industry Ventures AG

Marcel R. Gamma – CEO & Chairman

M.A. Economics & Finance (lic. oec. HSG) / MBA

ceo@swiss-ventures.com

Office +41 44 244 07 10

Legal Disclaimer



This presentation contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of CBD of Denver Inc. (the "Company") with members of its management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

The content of this report has been prepared by a third-party that has been compensated by the company in cash to produce the report. The report is intended to be used and must be used for informational purposes only. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find in this report or on our website and wish to rely upon, whether for the purpose of making an investment decision or otherwise.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy of such third-party information. We did not make an independent investigation or inquiry as to the accuracy of any information provided by third party sources. All information regarding the Company itself is contained in other publicly available press releases or filings made by the Company including reports posted on OTCMarkets.com.

Independent accountants have neither audited, reviewed, examined nor compiled any of the historical, pro forma, budgeted or prospective financial information presented herein or expressed any opinion or conclusion thereon or any other form of assurance with respect thereof.

The report does not take into account the investment objectives, financial situation, or particular needs of any particular person. The report does not provide all information material to an investor's decision about whether or not to make any investment. Companies that typically trade on the OTC market, such as the Company, are at an early stage in their evolution, tend to trade with big price swings and typically carry above-average risk profiles. Any discussion of risks is not a disclosure of all risks or a complete discussion of the risks mentioned.